Liquid biopsy: ready to guide therapy in advanced prostate cancer?
about
Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.Molecular biomarkers to guide precision medicine in localized prostate cancer.The Non-Coding Transcriptome of Prostate Cancer: Implications for Clinical Practice.Liquid biopsy: a step forward towards precision medicine in urologic malignancies.Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis.Non-blood circulating tumor DNA detection in cancer.Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine.Tissue-based biomarkers in prostate cancer.Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer.Immunogenetics of prostate cancer: a still unexplored field of study.Isolation and Characterization of CTCs from Patients with Cancer of a Urothelial Origin.Non-invasive actionable biomarkers for metastatic prostate cancer.Expression of Epithelial Mesenchymal Transition and Cancer Stem Cell Markers in Circulating Tumor Cells.Novel AR-V7 detection in whole blood samples in patients with prostate cancer: not as simple as it seems.Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns.Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutionsLiquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring
P2860
Q38644658-68A7D355-259E-4329-8083-6B0C470E5E5CQ38668635-8E011C6C-3530-4561-8C75-27D5F72FBFD4Q38744451-A3A1519E-1CD9-488D-B231-25B727DFC693Q39243268-1BF1DD02-7EAB-48E2-8ACA-49E465174F6BQ39424549-B3CB3258-CE9D-4416-90E4-E2B394B46E55Q42253044-EBA7C842-C57B-4283-A8B8-7AE10A943E63Q47110040-E3D5FB78-8561-4087-B819-4B200F022E41Q47144748-B8EB6AA2-A137-4E23-A34E-4A95A1483B1CQ47563953-ACD3BE74-3610-4125-A83F-0FDD220FE13DQ49728493-0764C86D-43D1-4D1B-9646-B39719790D18Q50082109-AA3574AB-63B3-4C31-962F-78D36205AB2CQ50182593-2E24675E-F7A6-4C90-BB34-51468BEB46C5Q51789456-E5BF958E-DD00-43FF-B732-CCEC071E5BFBQ52864004-06CE0E00-5DFD-4EC2-945C-06CE975D34E2Q53474740-F3199C47-8374-4896-84A1-B6D2F90F9FC9Q53721511-2A04B1FE-F058-4646-9CCD-5FA2EF854B52Q58698705-5482E717-747E-4925-9EFF-C34770F15C70Q58704141-2C373EC7-5F93-4848-BF6A-0A95A6E8DEA9
P2860
Liquid biopsy: ready to guide therapy in advanced prostate cancer?
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Liquid biopsy: ready to guide therapy in advanced prostate cancer?
@en
type
label
Liquid biopsy: ready to guide therapy in advanced prostate cancer?
@en
prefLabel
Liquid biopsy: ready to guide therapy in advanced prostate cancer?
@en
P2093
P2860
P356
P1433
P1476
Liquid biopsy: ready to guide therapy in advanced prostate cancer?
@en
P2093
Arnulf Stenzl
Miriam Hegemann
Peter C Black
Tilman Todenhöfer
P2860
P304
P356
10.1111/BJU.13586
P50
P577
2016-07-19T00:00:00Z